All News

Dr. Joshua Sabari explains how surgery, radiation and therapy may reduce lung capacity and shares steps survivors can take to protect breathing health.

Through personal stories and a research study on group drumming, Chester Freeman explores the reality of "chemo brain" and the power of finding rhythm in recovery.

Dr. Suneel Kamath walks patients through what they need to know about their gastrointestinal cancers following major oncology meetings.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies.

The FDA cleared a phase 3 trial for iSCIB1+ after data showed 74% progression-free survival at 16 months for patients with advanced melanoma.

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

CURE recently spoke with CEPHEUS study investigator Dr. Saad Z. Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center.

A gynecologic oncologist discusses staging, treatment choices, sexual health, mental health and HPV vaccination during cervical cancer awareness month.

Dr. Suneel Kamath addresses patient concerns on the topic of clinical trial participation in the gastrointestinal cancer treatment space.

Losing my cat after years alongside my cancer journey reminded me how much his presence eased stress, anxiety and treatment days.

The FDA accepted a new drug application for zanzalintinib plus immunotherapy after showing improved survival in some previously treated colorectal cancers.

An expert explains FDA-approved Lymphir for relapsed or refractory CTCL, noting 36% response rate, manageable side effects and fast relief from itching.

A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic castration-sensitive prostate cancer.

Clinical trial data shows that the protein CD47 may predict how well evorpacept works for patients with metastatic breast cancer.

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma.

Biotin supplements used for cancer-related hair loss may interfere with key blood tests, risking inaccurate results and altered care decisions.

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers.

Stage 2 ccRCC is treated with surgery, and patients should discuss partial nephrectomy, adjuvant therapy, and follow-up care with their oncology team.

Smoldering multiple myeloma is a complex, intermediary stage of plasma cell disorders that requires a nuanced approach to care.

Lung carcinoid tumors are rare and often slow growing. Treatment depends on stage and tumor type, with surgery common early and systemic options for advanced disease.

Dr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium.

Adding Ibrance to maintenance therapy extends the time some patients with metastatic breast cancer live without their disease progressing.

Risk assessment helps patients understand why cancer occurred, the role of genetics, treatment options and prevention strategies for themselves and family.

I’m preparing for something I once only dreamed about, my final visit to the cancer treatment center.

Dr. Brittany Dulmage explains how biotin can interfere with lab testing and discusses safer, evidence-based options for managing cancer-related hair loss.

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after prior targeted treatment.

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.